Forest Expects Benicar Sales To Increase With 80 Additional Sankyo Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest expects sales for the antihypertensive Benicar (olmesartan) to increase due to an additional 80 reps from its co-promotion partner Sankyo